天目药业: 杭州天目山药业股份有限公司关于董事兼高级管理人员辞职、调整董事会专门委员会委员及聘任高级管理人员的公告

Core Viewpoint - The announcement details the resignation of Wang Yihui, the company's director and CFO, due to job relocation, and the subsequent appointments of new senior management personnel and adjustments to the board's specialized committees [1][2]. Group 1: Resignation of Senior Management - Wang Yihui submitted her resignation as a director, strategic committee member, and CFO, effective immediately upon delivery to the board [1][2]. - Her resignation will not affect the board's minimum number of members or the company's daily operations, and she has no outstanding commitments or obligations to the company [2]. Group 2: Appointment of New Senior Management - The company appointed Han Tongmin as the new vice president and Dang Guojun as the new CFO, effective from the date of the board's approval [1][2][3]. - Both new appointees have no prior stock holdings in the company and meet all legal and regulatory requirements for their positions [5][6]. Group 3: Adjustment of Board Committees - The board approved the adjustment of its specialized committees, electing non-independent director Huang Junde as a member of the Compensation and Assessment Committee [4]. - The current members of the Compensation and Assessment Committee are Pei Yang (Chairman), Sheng Xiaomeng, and Huang Junde [4].